Evolution of precision medicine in cardiovascular care on-demand webinar

July 29, 2021

Torrey Loper

The Evolution of Precision Medicine in Cardiovascular Care Webinar – Originally recorded Tuesday, July 27th , 2021

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.

Real-World Evidence

Acute Valve Syndrome in Aortic Stenosis

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly

Press

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR) Key Findings Demonstrate 3x Improved Survival for Asymptomatic AS Patients Undergoing AVR versus AS Patients Presenting with Acute Valve Syndrome ALISO VIEJO, Calif. – October 28, 2024 – egnite, Inc., a leading cardiovascular digital

Evolution of precision medicine in cardiovascular care on-demand webinar

Related Articles

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams

Acute Valve Syndrome in Aortic Stenosis

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)